Literature DB >> 605916

Exacerbation of diabetic renal failure following intravenous pyelography.

S Harkonen, C M Kjellstrand.   

Abstract

Twenty-two of 29 (76 per cent) diabetic patients with a creatinine level of more than 2 mg/100 ml had exacerbation of renal failure following intravenous pyelography. In nine patients this was irreversible. Particularly at risk seem to be patients with early onset diabetes (less than 40 years), and those patients with severe renal failure (creatine over 5 mg/100 ml). No less that 15 of 16 (93 per cent) such patients had problems after intravenous pyelography; of these, nine (56 per cent) had irreversible deterioration. This report, in context with the increasing number of case reports of similar findin.gs, indicates that intravenous pyelography is dangerous in patients with juvenile onset diabetes who have a creatinine level of more than 5 mg/100 ml.

Entities:  

Mesh:

Year:  1977        PMID: 605916     DOI: 10.1016/0002-9343(77)90549-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  6 in total

Review 1.  Contrast-induced acute kidney injury and diabetic nephropathy.

Authors:  Andrew D Calvin; Sanjay Misra; Axel Pflueger
Journal:  Nat Rev Nephrol       Date:  2010-09-28       Impact factor: 28.314

Review 2.  Should nonionic radiographic contrast media be given to all patients?

Authors:  P S Parfrey; B C Cramer; P J McManamon
Journal:  CMAJ       Date:  1988-03-15       Impact factor: 8.262

3.  Acute renal failure.

Authors: 
Journal:  Br Med J       Date:  1980-06-07

4.  Contrast-induced nephropathy following chronic total occlusion percutaneous coronary intervention in patients with chronic kidney disease.

Authors:  Yuan-Hui Liu; Yong Liu; Ning Tan; Ji-Yan Chen; Ying-Ling Zhou; Jian-Fang Luo; Dan-Qing Yu; Li-Wen Li; Hua-Long Li; Piao Ye; Peng Ran
Journal:  Eur Radiol       Date:  2015-05-17       Impact factor: 5.315

5.  Preserving renal function in surgical patients.

Authors:  C Whiteside-Yim; F T Fitzgerald
Journal:  West J Med       Date:  1987-03

Review 6.  ACE-I/ARB therapy prior to contrast exposure: what should the clinician do?

Authors:  Robert Kalyesubula; Peace Bagasha; Mark A Perazella
Journal:  Biomed Res Int       Date:  2014-01-29       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.